| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Cerenome, Inc.: Cerenome Secures In-Network Agreement with Florida Blue for CNSide CSF Tumor Cell Enumeration and Molecular Profile Tests | 23 | GlobeNewswire (USA) | ||
| 06.10. | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | 273 | GlobeNewswire (Europe) | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| 02.10. | CERENOME, INC. - 8-K, Current Report | 12 | SEC Filings | ||
| 30.09. | Cerenome, Inc.: Cerenome Expects $1.55 Million in CNSide Third Quarter Gross Billings | 234 | GlobeNewswire (Europe) | Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30... ► Artikel lesen | |
| 25.09. | Cerenome, Inc.: Cerenome to Hold CNSide Business Update Call on September 30, 2026 | 2 | GlobeNewswire (USA) | ||
| 22.09. | CNSide Diagnostics signs agreement with Blue Cross Michigan | 1 | Investing.com | ||
| 22.09. | Cerenome, Inc.: Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide Contracted Coverage to Approximately 158 Million Covered Lives | 3 | GlobeNewswire (USA) | ||
| CERENOME Aktie jetzt für 0€ handeln | |||||
| 16.09. | Cerenome Appoints Samantha Fowlkes As Vice President And Head Of Commercial Sales For CNSide Diagnostics | 1 | pulse2.com | ||
| 16.09. | Cerenome beruft Samantha Fowlkes zur Vertriebsleiterin von CNSide Diagnostics | 4 | Investing.com Deutsch | ||
| 16.09. | Cerenome appoints Samantha Fowlkes as commercial sales head | 3 | Investing.com | ||
| 16.09. | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | 518 | GlobeNewswire (Europe) | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| 10.09. | CERENOME, INC. - 8-K, Current Report | 10 | SEC Filings | ||
| 10.09. | Cerenome, Inc.: Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment | 566 | GlobeNewswire (Europe) | Capital will support continued CNSide commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028... ► Artikel lesen | |
| 17.08. | Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook | 22 | Seeking Alpha | ||
| 14.08. | Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update | 583 | GlobeNewswire (Europe) | HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics... ► Artikel lesen | |
| 13.08. | Cerenome, Inc.: Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide Contracted Coverage to Over 150 Million Covered Lives | 23 | GlobeNewswire (USA) | ||
| 06.08. | Cerenome subsidiary selects XiFin for diagnostic billing services | 11 | Investing.com | ||
| 04.08. | CERENOME, INC. - 8-K, Current Report | 32 | SEC Filings | ||
| 03.08. | Plus Therapeutics Rebrands with Launch of Cerenome | 2 | Contract Pharma | ||
| 31.07. | Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company | 722 | GlobeNewswire (Europe) | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 45,075 | +2,78 % | VW und Autobauer im Fokus: DAX vor dem nächsten Schub? Diese Woche wird für Anleger entscheidend | © Foto: Boris Roessler/dpaDer DAX dürfte freundlich in die neue Woche starten. Auch die europäischen Futures liegen im Plus. Doch Öl, Inflation und die beginnende US-Berichtssaison könnten schnell für... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,540 | +0,20 % | CFO-News: Aumovio, Fresenius Medical Care, Verbund | ||
| SIEMENS HEALTHINEERS | 41,450 | +1,47 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,760 | +0,06 % | DEUTSCHE BANK RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Carl Zeiss Meditec vor Zahlen auf "Hold" mit einem Kursziel von 26 Euro belassen. Das Medizintechnik-Unternehmen dürfte ein... ► Artikel lesen | |
| ECKERT & ZIEGLER | 12,750 | +3,49 % | Eckert & Ziegler: Independence gains value: Recent radiopharma transactions highlight the strategic value of EUZ's independent ... | Recent radiopharma acquisitions underline the value of EUZ's core capabilities: independent isotope supply and specialist manufacturing. Strategic and financial investors are acquiring comparable isotope... ► Artikel lesen | |
| INTUITIVE SURGICAL | 379,10 | -0,16 % | Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside | ||
| UNITEDHEALTH | 358,80 | +0,39 % | Ihre wichtigsten Termine: Johnson & Johnson, UnitedHealth, JPMorgan und Wells Fargo legen neue Zahlen vor! | © Foto: Jens Kalaene - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0382221051... ► Artikel lesen | |
| DRAEGERWERK | 95,70 | -0,62 % | Draegerwerk AG & Co. KGaA: Q3-EBIT enttäuscht, Jahresziele für 2026 bleiben aber erreichbar; KAUFEN | Dräger hat vorläufige Zahlen für das dritte Quartal 2026 vorgelegt, die ein moderates Umsatzwachstum, jedoch eine schwächere operative Profitabilität zeigen - und das trotz eines signifikant positiven... ► Artikel lesen | |
| MEDTRONIC | 83,94 | -0,47 % | 6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzen | ||
| GERRESHEIMER | 30,440 | +6,06 % | EQS-PVR: Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Gerresheimer AG
Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
12.10.2026 / 17:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| THERMO FISHER | 613,80 | -0,07 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| TELADOC HEALTH | 5,168 | +2,34 % | Teladoc Health, Inc.: Teladoc Health to Announce Third Quarter 2026 Financial Results | ||
| STRATEC | 23,650 | -2,27 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,89 | +0,03 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,340 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen |